Barclays
AUPH icon

Barclays’s Aurinia Pharmaceuticals AUPH Stock Holding History

Barclays’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-42,500
Closed -$213K – 4863
2024
Q1 		$213K Buy
42,500
+9,500
+29% +$64.4K ﹤0.01% 4087
2023
Q4 		$297K Buy
+33,000
New +$272K ﹤0.01% 4213
2022
Q1 		– Sell
-31,200
Closed -$714K – 4939
2021
Q4 		$714K Buy
+31,200
New +$739K ﹤0.01% 3018
2020
Q1 		– Sell
-9,900
Closed -$201K – 6127
2019
Q4 		$201K Sell
9,900
-132,600
-93% -$1.22M ﹤0.01% 5023
2019
Q3 		$761K Buy
+142,500
New +$862K ﹤0.01% 3900
2019
Q1 		– Sell
-50,000
Closed -$341K – 6993
2018
Q4 		$341K Hold
50,000
– – ﹤0.01% 4168
2018
Q3 		$332K Buy
+50,000
New +$280K ﹤0.01% 4600

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return